FMP
Nov 20, 2025
Central Garden & Pet Company, listed on NASDAQ under the symbols CENT and CENTA, is a key player in the pet and garden industries. The company is set to release its fourth quarter and fiscal year 2025 financial results on November 24, 2025. This announcement will provide insights into the company's performance for the period ending September 27, 2025.
Wall Street estimates suggest an earnings per share (EPS) of -$0.20 for NASDAQ:CENTA. Despite this anticipated loss, there is optimism that the company might surpass these expectations. The Zacks Consensus Estimate aligns with this prediction, also forecasting a quarterly loss of $0.20 per share. The revenue for this period is projected to be approximately $657.86 million.
NASDAQ:CENTA's financial metrics provide a deeper understanding of its market valuation. The company's price-to-earnings (P/E) ratio is approximately 12.32, indicating how the market values its earnings. The price-to-sales ratio is about 0.57, suggesting a relatively low market valuation compared to its sales. Additionally, the enterprise value to sales ratio is 0.80, showing that the enterprise value is slightly higher than its sales.
The company's liquidity and debt levels are also noteworthy. With a current ratio of 3.56, CENTA demonstrates strong liquidity, indicating its ability to cover short-term liabilities. The debt-to-equity ratio is 0.90, reflecting a moderate level of debt compared to equity. These figures suggest that CENTA is in a stable financial position, which could influence investor sentiment.
The upcoming earnings call, led by CEO Niko Lahanas and CFO Brad Smith, will be crucial in determining the sustainability of any immediate price changes and future earnings expectations. The management's discussion on business conditions will provide valuable insights into the company's strategy and outlook, potentially impacting the stock's near-term price movement.
NetEase, Inc. (NASDAQ:NTES) is a leading provider of internet and game services, known for its innovative gaming experie...
NovaBridge Biosciences (NASDAQ:NBP) is a biotech company dedicated to developing immuno-oncology agents for cancer treat...